Cargando…

Clinical Course of Infliximab Treatment in Korean Pediatric Ulcerative Colitis Patients: A Single Center Experience

PURPOSE: Infliximab (IFX) is considered safe and effective for the treatment of ulcerative colitis (UC) in both adults and children. The aim of this study was to evaluate the short- and long-term clinical course of IFX in Korean children with UC. METHODS: Pediatric patients with UC who had received...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jong Min, Lee, Yoo Min, Kang, Ben, Choe, Yon Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990780/ https://www.ncbi.nlm.nih.gov/pubmed/24749085 http://dx.doi.org/10.5223/pghn.2014.17.1.31

Ejemplares similares

Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy
por: Kim, Mi Jin, et al.
Publicado: (2021)

Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
por: Song, Won Jae, et al.
Publicado: (2016)

Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
por: Puthoor, Pamela R., et al.
Publicado: (2013)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study
por: Kim, Eun Hye, et al.
Publicado: (2015)

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
por: deBruyn, Jennifer C. C., et al.
Publicado: (2021)

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
por: Viscido, Angelo, et al.
Publicado: (2019)

How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience
por: Yamada, Satoshi, et al.
Publicado: (2014)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2019)

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
por: Seo, Hyun Il, et al.
Publicado: (2014)

Pediatric ulcerative colitis: current treatment approaches including role of infliximab
por: Bradley, Gia M, et al.
Publicado: (2012)

Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn’s Disease Patients
por: Choi, Jaeyoung, et al.
Publicado: (2018)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2017)

Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up
por: Lee, Yun Seok, et al.
Publicado: (2012)

Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
por: Kim, Yoon-Zi, et al.
Publicado: (2023)

Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients
por: Chun, Ji Young, et al.
Publicado: (2013)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Promising effect of infliximab on the extent of involvement in ulcerative colitis
por: Adibi, Peyman, et al.
Publicado: (2011)

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update
por: Lawlor, Garrett, et al.
Publicado: (2009)

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
por: Fasanmade, Adedigbo A., et al.
Publicado: (2009)

Pericardial Effusion due to Infliximab Therapy for Ulcerative Colitis
por: Mirza, Muhammad, et al.
Publicado: (2018)

Neutrophil-to-Platelet Ratio in Patients with Ulcerative Colitis Treated with Infliximab or Vedolizumab: A Retrospective, Single-Center Study in Poland
por: Warpechowski, Marcin, et al.
Publicado: (2023)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
por: Mir, Fazia A., et al.
Publicado: (2018)

Listeria Meningitis during Infliximab-based Treatment for Ulcerative Colitis
por: Tsuchiya, Atsunori, et al.
Publicado: (2018)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis
por: Gordon, Benjamin L., et al.
Publicado: (2023)

Successfully Treated Acute Fulminant Myocarditis Induced by Ulcerative Colitis with Extracorporeal Life Support and Infliximab
por: Kim, Han-Kyul, et al.
Publicado: (2016)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Clinical Characteristics and Long-term Outcomes of Pediatric Ulcerative Colitis: A Single-Center Experience in Korea
por: Jang, Jooyoung, et al.
Publicado: (2022)

Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands
por: Chaudhary, Mohammad A., et al.
Publicado: (2012)

Linear IgA dermatosis after infliximab infusion for ulcerative colitis
por: Bryant, Kelli D., et al.
Publicado: (2016)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis
por: Nishida, Yu, et al.
Publicado: (2017)

Disseminated Nocardiosis Associated with Treatment with Infliximab in a Patient with Ulcerative Colitis
por: Garner, Orlando, et al.
Publicado: (2017)

Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis
por: Liu, Yi-Juan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pes7t2veqq0u35asaq09qnlo0j